- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2017
- Public Summary Document (PSD) July 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2017 PBAC Meeting - Word
Pembrolizumab – July 2017
Pembrolizumab: Powder for injection 50 mg, Solution for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
10 November 2017